Repligen Corporation (RGEN)
Largest Insider Buys in Sector
RGEN Stock Price History Chart
RGEN Stock Performance
About Repligen Corporation
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput …
Insider Activity of Repligen Corporation
Over the last 12 months, insiders at Repligen Corporation have bought $600,476 and sold $14.08M worth of Repligen Corporation stock.
On average, over the past 5 years, insiders at Repligen Corporation have bought $316,041 and sold $21.15M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Madaus Martin D (director) — $605,328. BARTHELEMY NICOLAS (director) — $451,620. Hunt Anthony (Chief Executive Officer) — $248,160.
The last purchase of 1,615 shares for transaction amount of $201,776 was made by Madaus Martin D (director) on 2024‑06‑14.
List of Insider Buy and Sell Transactions, Repligen Corporation
| 2024-09-10 | Sale | director | 22,191 0.0393% | $145.37 | $3.23M | -4.57% | ||
| 2024-08-02 | Sale | Senior VP, R&D | 7,148 0.0126% | $159.35 | $1.14M | -10.47% | ||
| 2024-08-01 | Sale | Senior VP, R&D | 4,465 0.008% | $165.67 | $739,717 | -12.49% | ||
| 2024-06-14 | Chief Executive Officer | 2,000 0.0032% | $124.08 | $248,160 | +13.06% | |||
| 2024-06-14 | director | 1,200 0.0019% | $125.45 | $150,540 | +13.06% | |||
| 2024-06-14 | director | 1,615 0.0026% | $124.94 | $201,776 | +13.06% | |||
| 2024-05-21 | Sale | Chief Executive Officer | 20,072 0.0362% | $168.26 | $3.38M | -14.24% | ||
| 2024-03-11 | Sale | Senior VP, R&D | 3,517 0.0063% | $193.73 | $681,348 | -22.05% | ||
| 2024-03-08 | Sale | Chief Executive Officer | 16,707 0.0302% | $197.44 | $3.3M | -22.83% | ||
| 2024-02-27 | Sale | director | 1,000 0.0018% | $193.35 | $193,350 | -20.63% | ||
| 2024-02-23 | Sale | Chief Operating Officer | 4,373 0.0079% | $198.08 | $866,204 | -21.73% | ||
| 2023-11-10 | Sale | See Remarks | 3,788 0.0068% | $147.13 | $557,328 | +11.09% | ||
| 2023-08-29 | Sale | director | 850 0.0015% | $171.38 | $145,673 | -4.37% | ||
| 2023-05-08 | director | 500 0.0009% | $156.18 | $78,090 | +6.26% | |||
| 2023-05-05 | director | 500 0.0009% | $159.19 | $79,595 | +3.85% | |||
| 2023-05-04 | director | 500 0.0009% | $161.15 | $80,575 | +5.78% | |||
| 2023-02-16 | Sale | Chief Financial Officer | 5,647 0.0103% | $200.00 | $1.13M | -16.55% | ||
| 2022-11-11 | Sale | Chief Executive Officer | 25,000 0.0452% | $200.00 | $5M | -16.33% | ||
| 2022-09-09 | Sale | 775 0.0014% | $227.17 | $176,057 | -26.55% | |||
| 2022-09-08 | Sale | Chief Executive Officer | 6,626 0.0118% | $224.47 | $1.49M | -24.48% |
Insider Historical Profitability
| Hunt Anthony | director | 139840 0.2497% | $145.71 | 1 | 27 | |
| DAWES KAREN A | director | 87367 0.156% | $145.71 | 5 | 21 | +21.46% |
| BARTHELEMY NICOLAS | director | 4668 0.0083% | $145.71 | 1 | 7 | |
| Madaus Martin D | director | 4613 0.0082% | $145.71 | 4 | 0 | +5.3% |
| HERLIHY WALTER C | PRESIDENT, CEO | 262430 0.4686% | $145.71 | 1 | 15 | +58.42% |
Institutional Investor Ownership
| BlackRock | $1.43B | 13.91 | 7.77M | -1.1% | -$15.91M | 0.03 | |
| The Vanguard Group | $937.99M | 9.13 | 5.1M | +0.43% | +$3.99M | 0.02 | |
| T. Rowe Price | $656.29M | 6.39 | 3.57M | -11.02% | -$81.28M | 0.08 | |
| Fidelity Investments | $415.25M | 4.04 | 2.26M | +19.93% | +$69.02M | 0.03 | |
| State Street | $323.37M | 3.15 | 1.76M | +3.21% | +$10.04M | 0.01 |